Result:
Result: Lorem ipsum simply dummy text Lorem ipsum simply dummy text Lorem ipsum
Explore diverse prescription solutions in our A-Z pharmaceutical product catalog.
View by-
Hetero Healthcare Ltd began its marketing operations in India with the launch of Antiretrovirals (ARVs) and has gained prominence in the field of HIV/AIDS. We Manufacture and market major classes of ARVs as mono drugs, dual or triple-drug FDCs and differential packaging to improve patient compliance.
The biologics vertical was conceptualized in the year 2009. With the identification of key Biosimilars and helmed by a multi-disciplinary team of over 200 specialists, R&D commenced soon at the Hetero Research Foundation(HRF).
Hetero Healthcare has launched multiple antiviral medicines in one year to fight Corona with a determination to contribute to the vision "COVID-free India."
Hetero Healthcare have come to the world to help millions with a new approach to Diabetes management digitally. We offer complete solutions to Diabetes management (Dia) with & (Spa like) Rejuvenation.
In the Paediatric segment Frenza addressing Paediatric Respiratory & Gastroenterology issues. In Gynaecology addresses the woman healthcare from Conception to Lactation and Vaginal Wellness.
The purpose of launching Alpha Division (Generics) was to ensure our presence with the masses even at the micro interiors. We at Hetero, believes in giving quality of medicines at affordable prices.
GENX a Division of Hetero Healthcare is one of the major contributors to Hetero Healthcare Ltd. having a turnover of 1200 million. GENX is committed to providing products and services of quality.
Hetero Hepatology is committed towards creating awareness about Hepatitis B and C, providing access to high quality medicines at affordable rates and enriching lives of patients.
HHCL is a main Division of Hetero Healthcare Ltd with a clear intent of becoming a strong Healthcare Solution provider. At HHCL, we achieve customer satisfaction by providing products and services.
KRIS Division that started in 2010, today KRIS commands the highest growth with a progressive trend. Today, with a domestic market share of 1.01 percent in its represented market and the business growing three-fold between 2010-2015.
Hetero Oncology commercializes portfolio of Oncology and Hematology products to address the unmet medical needs of people with cancer and related diseases.
Hetero Healthcare R & D Centre had developed across a vast area. A striking feature of Hetero Healthcare is the well-planned and comprehensive infrastructure provided at this division.
Ultra Division – the OTC division of Hetero healthcare focuses on over-the-counter (OTC) medicines and sexual wellness products.
VOLGA a super speciality division with focus on Urology & Nephrology ailments has been launched in the year 2016. The initial focus in Nephrology segment is anaemia caused due to CKD.
The biologics vertical was conceptualized in the year 2009. With the identification of key Biosimilars and helmed by a multi-disciplinary team of over 200 specialists, R&D commenced soon at the Hetero Research Foundation(HRF). Hetero Biosimilars has enabled the company to join select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (mABs).Hetero has successfully launched Biosimilars of Darbepoetin alfa, Rituximab, Bevacizumab and Adalimumab and also has an ambitious pipeline of other Biosimilars.With this strength in Biosimilars "ASRA" division was carved out to serve the patients in need of Biosimilars for treating rheumatologic conditions.Over 2000 patients in India in the field of Rheumatology & Dermatolgy, are benefited by MABURA & MABAL-RA Biosimilars of Adalimumab and Rituximab and still going strong.
